Clinical Trials

Papers
(The TQCC of Clinical Trials is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)75
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial53
Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification49
Endpoints for randomized controlled clinical trials for COVID-19 treatments48
Cluster over individual randomization: are study design choices appropriately justified? Review of a random sample of trials25
COVID-19 vaccine trials: The use of active controls and non-inferiority studies23
Use of electronic recruitment methods in a clinical trial of adults with gout22
User-centered design principles in the development of clinical research tools21
The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials20
Effectiveness of social media (Facebook), targeted mailing, and in-person solicitation for the recruitment of young adult in a diabetes self-management clinical trial20
Intra-cluster correlations from the CLustered OUtcome Dataset bank to inform the design of longitudinal cluster trials19
Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods19
Summarising salient information on historical controls: A structured assessment of validity and comparability across studies18
Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff18
Characteristics of available studies and dissemination of research using major clinical data sharing platforms16
Commentary on Parker and Weir15
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)15
Mindfulness, Education, and Exercise for age-related cognitive decline: Study protocol, pilot study results, and description of the baseline sample15
Blinding, sham, and treatment effects in randomized controlled trials for back pain in 2000–2019: A review and meta-analytic approach14
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–201813
An ethics framework for consolidating and prioritizing COVID-19 clinical trials13
Retrospective collection of 90-day modified Rankin Scale is accurate13
Incorporating estimands into clinical trial statistical analysis plans13
The U.S. Food and Drug Administration’s Complex Innovative Trial Design Pilot Meeting Program: Progress to date13
Trends and variation in data quality and availability on the European Union Clinical Trials Register: A cross-sectional study12
The DURATIONS randomised trial design: Estimation targets, analysis methods and operating characteristics12
Phase I trial compensation: How much do healthy volunteers actually earn from clinical trial enrollment?12
Randomized comparison of two interventions to enhance understanding during the informed consent process for research12
Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial12
Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial11
Strategies for research participant engagement: A synthetic review and conceptual framework11
Clarifying selection bias in cluster randomized trials11
Strategies for facilitating the delivery of cluster randomized trials in hospitals: A study informed by the CFIR-ERIC matching tool11
Effectiveness of participant recruitment strategies for critical care trials: A systematic review and narrative synthesis11
Clinical trials site recruitment optimisation: Guidance from Clinical Trials: Impact and Quality10
When is it impractical to ask informed consent? A systematic review10
Now is the time to fix the evidence generation system10
Five analytic challenges in working with electronic health records data to support clinical trials with some solutions9
A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease9
Recruitment and retention in randomized controlled trials with urban American Indian/Alaska Native adolescents: Challenges and lessons learned9
Now is the time to fix the clinical research workforce crisis9
Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review9
Clinical trial monitoring effectiveness: Remote risk-based monitoring versus on-site monitoring with 100% source data verification9
Using modified intention-to-treat as a principal stratum estimator for failure to initiate treatment9
The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials8
Research Attitudes Questionnaire scores predict Alzheimer’s disease clinical trial dropout8
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer8
Influential methods reports for group-randomized trials and related designs8
COVID-19 impact on multi-site recruitment and enrollment8
The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States7
Exploring factors influencing recruitment results of nurses recruiting diabetes patients for a randomized controlled trial7
Are restricted mean survival time methods especially useful for noninferiority trials?7
Randomized controlled trial of an education-based intervention to improve medication adherence: Design considerations in the medication adherence in glaucoma to improve care study7
Timing is everything: The importance of patient-reported outcome assessment frequency when characterizing symptomatic adverse events7
Rethinking intercurrent events in defining estimands for tuberculosis trials7
Marginal modeling in community randomized trials with rare events: Utilization of the negative binomial regression model7
Recruiting an underserved, difficult to reach population into a cancer trial: Strategies from the Restore-2 Rehabilitation Trial for gay and bisexual prostate cancer patients7
Details of risk–benefit communication in informed consent documents for phase I/II trials7
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats7
Lack of harmonization of coronavirus disease ordinal scales7
Current recommendations/practices for anonymising data from clinical trials in order to make it available for sharing: A scoping review7
Patient accrual and understanding of informed consent in a two-stage consent design7
The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks6
Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review6
Adjusting for adherence in randomized trials when adherence is measured as a continuous variable: An application to the Lipid Research Clinics Coronary Primary Prevention Trial6
Recruiting breast cancer patients for mHealth research: Obstacles to clinic-based recruitment for a mobile phone app intervention study6
Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance6
Why restricted mean survival time methods are especially useful for non-inferiority trials6
Improving efficiency in the stepped-wedge trial design via Bayesian modeling with an informative prior for the time effects6
Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape6
Quantification of hematoma and perihematomal edema volumes in intracerebral hemorrhage study: Design considerations in an artificial intelligence validation (QUANTUM) study6
The triple aim of clinical research6
Developing an online, searchable database to systematically map and organise current literature on retention research (ORRCA2)6
Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention6
Demographic diversity of US-based participants in GSK-sponsored interventional clinical trials5
Comparison of survival distributions in clinical trials: A practical guidance5
The APPROACH trial: Assessing pain, patient-reported outcomes, and complementary and integrative health5
Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis5
Exploring mechanisms of action in clinical trials of complex surgical interventions using mediation analysis5
Impact of complex, partially nested clustering in a three-arm individually randomized group treatment trial: A case study with the wHOPE trial5
Reopening schools safely in the face of COVID-19: Can cluster randomized trials help?5
Navigating the ethics of remote research data collection5
Double-blinding of an acupuncture randomized controlled trial optimized with clinical translational science award resources5
Results publications are inadequately linked to trial registrations: An automated pipeline and evaluation of German university medical centers5
Methodological challenges in pragmatic trials in Alzheimer’s disease and related dementias: Opportunities for improvement5
The maraca plot: A novel visualization of hierarchical composite endpoints5
Time trends with response-adaptive randomization: The inevitability of inefficiency5
Making a distinction between data cleaning and central monitoring in clinical trials5
Facilitating clinical research through automation: Combining optical character recognition with natural language processing5
A Bayesian response-adaptive dose-finding and comparative effectiveness trial5
Data monitoring committee interim reports: We must get there soon!5
Joint testing of overall and simple effects for the two-by-two factorial trial design5
Cost-benefit of outcome adjudication in nine randomised stroke trials5
Ethics challenges in sharing data from pragmatic clinical trials5
Analysis of adaptive platform trials using a network approach4
Intent-to-treat analysis of cluster randomized trials when clusters report unidentifiable outcome proportions4
From screening to ascertainment of the primary outcome using electronic health records: Challenges in the STRIDE trial4
Interim data monitoring in cluster randomised trials: Practical issues and a case study4
A modular framework for early-phase seamless oncology trials4
Clinical trials in the time of a pandemic4
Proceedings of the University of Pennsylvania 12th annual conference on statistical issues in clinical trials: Electronic health records (EHR) in randomized clinical trials—Challenges and opportunitie4
Data management in substance use disorder treatment research: Implications from data harmonization of National Institute on Drug Abuse-funded randomized controlled trials4
Use of information criteria for selecting a correlation structure for longitudinal cluster randomised trials4
Barriers to uptake of the hip fracture core outcome set: An international survey of 80 hip fracture trialists4
When and how to include vulnerable subjects in clinical trials4
Backfilling cohorts in phase I dose-escalation studies4
Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials4
Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer4
Choosing and changing the analysis scale in non-inferiority trials with a binary outcome4
Covariate adjustment in subgroup analyses of randomized clinical trials: A propensity score approach4
Measures of fidelity of delivery and engagement in self-management interventions: A systematic review of measures4
Clinical Trials to authors: Please pre-register your studies!4
Bayesian basket trial design with false-discovery rate control4
Commentary: Two approaches to analyze platform trials incorporating non-concurrent controls with a common assumption4
Improving clinical trial transparency at UK universities: Evaluating 3 years of policies and reporting performance on the European Clinical Trial Register4
0.031967878341675